Haloperidol Decanoate

Summary

Haloperidol Decanoate (CHEMBL1200986) is an approved small molecule; indicated across 2 conditions including delirium.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 11
• Chemistry: 530.1 Da · C31H41ClFNO3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200986
Name	Haloperidol Decanoate
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	52919
Molecular formula	C31H41ClFNO3
Molecular weight	530.1
InChIKey	GUTXTARXLVFHDK-UHFFFAOYSA-N

SMILES: CCCCCCCCCC(=O)OC1(CCN(CC1)CCCC(=O)C2=CC=C(C=C2)F)C3=CC=C(C=C3)Cl

IUPAC name: [4-(4-chlorophenyl)-1-[4-(4-fluorophenyl)-4-oxobutyl]piperidin-4-yl] decanoate

Also known as: Haldol, Halomonth, Haloperidol decanoate, Haldol dec, R-13,672, R-13672, HALOPERIDOL DECANOATE, Haloperidol Decanoate, HALOPERIDOL-DECANOATE, haloperidol-decanoate

Patent coverage: 184 distinct patent families (591 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 4 (assay-derived). Sample: D(2) dopamine receptor, D(4) dopamine receptor, D(3) dopamine receptor, D(1A) dopamine receptor.

Bioactivity

ChEMBL activities: 5 potent at pChembl ≥ 5 of 5 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
DRD2	9.34	Ki	0.46	nM	CHEMBL_ACT_15012182
DRD2	8.74	Ki	1.8	nM	CHEMBL_ACT_15012156
DRD3	8.46	Ki	3.5	nM	CHEMBL_ACT_15012208
DRD4	8.24	Ki	5.8	nM	CHEMBL_ACT_15012234
P50130	6.85	Ki	140	nM	CHEMBL_ACT_15012260

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
delirium	2	MONDO:0045057	EFO:0009267

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 11.

Phase distribution

Phase	Trials
PHASE4	4
PHASE3	3
Not specified	3
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00947375	PHASE4	TERMINATED	Lamictal TM, Haloperidol Decanoate in Schizophrenia
NCT01136772	PHASE4	COMPLETED	A Comparison of Long-acting Injectable Medications for Schizophrenia
NCT01174290	PHASE4	COMPLETED	Preventing ICU Subsyndromal Delirium Conversion to Delirium With Haloperidol
NCT03489551	PHASE4	COMPLETED	Feasibility of Prophylactic Haldol to Prevent Delirium in Cancer Patients
NCT00124930	PHASE3	TERMINATED	Study Comparing Olanzapine With Haloperidol for the Relief of Nausea and Vomiting in Patients With Advanced Cancer
NCT04327843	PHASE3	COMPLETED	Reducing the Burden of Chronic Psychotic Disorders in Tanzania (CAPACITY)
NCT04833023	PHASE3	UNKNOWN	HALO Trial: Haloperidol vs Olanzapine in Hyperactive Delirium in Palliative Care Patients; A Multi-Centre, Randomised-Controlled Trial
NCT01949662	PHASE2	ACTIVE_NOT_RECRUITING	Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer
NCT00018642	Not specified	COMPLETED	Quetiapine vs Haloperidol Decanoate for the Long Term Treatment of Schizophrenia and Schizoaffective Disorder
NCT00493233	Not specified	COMPLETED	Antipsychotic Polypharmacy in Schizophrenia
NCT01152697	Not specified	COMPLETED	Customized Adherence Enhancement Plus Long-acting Injectable Antipsychotic

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).